Clinical trials: Cerebral Vascular Disorder
Cerebral Infarction
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
- Trial name
- NCT03186456
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Stroke, Hemiplegia
Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System
The objective of this study is to evaluate the efficacy and safety of surgical procedure involving ActiGait - implantable drop foot stimulator.
- Trial name
- NCT01116466
- Testing
- ActiGait
- Volunteers
- 5 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Intracranial Aneurysms
Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction
This study is designed to evaluate the safety of the PulseRider in patients undergoing treatment for bifurcation basilar or carotid terminus aneurysms.
- Trial name
- ANSWER (NCT02312856)
- Testing
- PulseRider
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pulsar Vascular
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01012674
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Guerbet
Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design.
- Conditions
- Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis
- Trial name
- NCT04103034
- Testing
- BT200, Desmopressin
- Where
- Austria
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Band Therapeutics
Cerebral Cavernous Malformation
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
This Phase 1, dose-escalation, double-blind, multiple ascending dose (MAD) study was designed to assess the safety and tolerability of NRL-1049 compared to placebo in healthy adult participants and to determine the maximum…
- Trial name
- NCT07908134
- Testing
- NRL-1049
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.
Stroke
OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)
1. To survey the health-related quality of life using the SF-36v2 score of patients with chronic brain infarction in Japan 2. Chronic brain infarction in Japan is better than EU/USA
- Trial name
- NCT00281034
- Where
- Japan
- Volunteers
- 2,069 people
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Wegener's Granulomatosis or Microscopic Polyangiitis
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
This is a perspective, Phase IV, multi-center, single arm, open-label, interventional study in adult participants with Wegener's granulomatosis (granulomatosis with polyangiitis [GPA]) or microscopic polyangiitis.
- Trial name
- NCT02115997
- Testing
- Methylprednisolone, Prednisone, Rituximab
- Where
- 10 sites in India
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Acute Ischemic Stroke
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
- Trial name
- XY03-EA (NCT05515393)
- Testing
- XY03-EA
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Cerebrovascular Accident
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting.
- Trial name
- NCT00562588
- Testing
- Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
SY007 in Patients With Acute Ischemic Stroke
This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke…
- Trial name
- NCT04891913
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to evaluate the safety and efficacy of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral disturbances associated with dementia.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT00253123
- Testing
- risperidone
- Volunteers
- 626 people
- Sponsor
- Janssen, LP
Intracranial Aneurysms
Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms
The primary objective of this registry is to assess the safety and angiographic outcomes of endovascular treatment of intracranial aneurysms using the DeltaMaxx Microcoil System.
- Trial name
- NCT01945827
- Testing
- DeltaMaxx Microcoil System
- Sponsor
- Codman & Shurtleff
Fabry Disease
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks.
- Trial name
- NCT04974749
- Testing
- REPLAGAL
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Aneurysm Cerebral, Bifurcation
LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan
The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA).
- Conditions
- Aneurysm Cerebral, Bifurcation, Unruptured Intracranial Aneurysm, Saccular Aneurysm
- Trial name
- NCT07259018
- Testing
- LuSeed Aneurysm Embolization System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- LuSeed Vascular LTD.
Cerebral Stroke
Telerehabilitation Early After Stroke
The goal of this clinical trial is to assess the safety and feasibility of providing extra doses of rehabilitation therapy for persons with a recent stroke.
- Trial name
- NCT05625438
- Testing
- HandyMotion Treatment Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- TRCare, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.